Chr del(5q)

News alerts, weekly reports and conference planners

Chr del(5q)	Myelodysplastic Syndrome	Chr del(5q)	Myelodysplastic Syndrome	lenalidomide Sensitive: A1 - Approval lenalidomide Sensitive : A1	lenalidomide Sensitive: A1 - Approval lenalidomide Sensitive : A1
Chr del(5q)	Acute Myelogenous Leukemia	Chr del(5q)	Acute Myelogenous Leukemia	venetoclax + ruxolitinib Resistant: C3 – Early Trials venetoclax + ruxolitinib Resistant : C3	venetoclax + ruxolitinib Resistant: C3 – Early Trials venetoclax + ruxolitinib Resistant : C3
Chr del(5q)	Acute Myelogenous Leukemia	Chr del(5q)	Acute Myelogenous Leukemia	cytarabine + decitabine + mitoxantrone Sensitive: C3 – Early Trials cytarabine + decitabine + mitoxantrone Sensitive : C3	cytarabine + decitabine + mitoxantrone Sensitive: C3 – Early Trials cytarabine + decitabine + mitoxantrone Sensitive : C3
Chr del(5q)	Myelodysplastic Syndrome	Chr del(5q)	Myelodysplastic Syndrome	VRD Sensitive: C4 – Case Studies VRD Sensitive : C4	VRD Sensitive: C4 – Case Studies VRD Sensitive : C4
Chr del(5q)	Multiple Myeloma	Chr del(5q)	Multiple Myeloma	VRD Sensitive: C4 – Case Studies VRD Sensitive : C4	VRD Sensitive: C4 – Case Studies VRD Sensitive : C4

Associations